top of page
>
>
Landscape assessment, development opportunities, and forecasting for novel prostate cancer molecule
Client Problems
A privately-held, development stage pharmaceutical company wanted to understand the current and future treatment landscape of prostate cancer, opportunities for novel platform development, and forecast peak year sales across several potential indications
TA has complex market dynamics, with other products gaining additional indications and targeted therapies expected to become more prominent in the market
What We Did
- Reviewed the current SOC and pipeline competitors to identify treatment gaps and likely evolution of standard of care.
- Assessed clinical development opportunities for potential indications alone or as a combination therapy
- We identified patient segments and estimated market sizing for each potential indication. Using this, we forecast a range of peak year sales based on variable clinical trial outcomes and different levels of patient share
Our Results And Insight
- Mapped the expected 2020+ Treatment Landscape, showing additional AR pathway drugs and the emergence of targeted therapies
- Used completed and on-going clinical trials in the TA as an analogue for expected clinical trial design
- Estimated potential opportunity for each indication
- Forecast peak year sales based on a range of clinical trial outcomes for each indication
See other case studies
Commercial Strategy case studies >
Oncology case studies >
Service Areas Details
Commercial Strategy (Market Forecast, Competitive Assessment)
Therapeutic Areas Details
Oncology (Solid Tumor, Prostate)
Featured Consultants
bottom of page